PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

Small molecule immune checkpoint inhibitors targeting PD-1 and other pathways may offer advantages including ease of dosing, ability to manage immune-related adverse events (irAEs) due to their shorter pharmacokinetic exposure and opportunity to target more than one pathway for improving efficacy. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasikumar, Pottayil G., Sudarshan, Naremaddepalli S., Adurthi, Srinivas, Ramachandra, Raghuveer K., Samiulla, Dodderi S., Lakshminarasimhan, Anirudha, Ramanathan, Anuradha, Chandrasekhar, Talapaneni, Dhudashiya, Amit A., Talapati, Sumalatha R., Gowda, Nagesh, Palakolanu, Sreenivasulareddy, Mani, Jiju, Srinivasrao, Bandi, Joseph, David, Kumar, Nigam, Nair, Rashmi, Atreya, Hanudatta S., Gowda, Nagaraj, Ramachandra, Murali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187357/
https://www.ncbi.nlm.nih.gov/pubmed/34103659
http://dx.doi.org/10.1038/s42003-021-02191-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187357/
https://www.ncbi.nlm.nih.gov/pubmed/34103659
http://dx.doi.org/10.1038/s42003-021-02191-1

Ejemplares similares